Congress’ pandemic prep effort receives mixed reviews Penn In the News Axios Congress’ pandemic prep effort receives mixed reviews PIK Professor Ezekiel Emanuel says that Congress’ bipartisan PREVENT Pandemics Act isn’t fixing the aspects that led to a bad COVID response, which doesn’t bode well for future variants and pandemics. Med schools should de-emphasize standardized admissions tests Penn In the News The Washington Post Med schools should de-emphasize standardized admissions tests In a cowritten Op-Ed, College of Arts and Sciences student Cameron Sabet urges medical schools to make their standardized tests pass/fail in order to remove barriers for disadvantaged minority applicants. A dynamic thinker Penn In the News Diverse: Issues in Higher Education A dynamic thinker A profile examines the career of Anita L. Allen of Penn Carey Law and the School of Arts & Sciences, who was recently named as one of two recipients of the Hastings Center’s 2022 Bioethics’ Founders Award. Tackling the ethical considerations of dementia research Tackling the ethical considerations of dementia research Alzheimer’s research poses tricky questions. Bedside-nurse-turned-bioethicist Emily Largent wants to answer them, and to improve the lives of Alzheimer’s patients. Going beyond the binary in historical explorations of sex and gender Beans Velocci, a faculty member in the Department of History and Sociology of Science, studies the complex and conflicting ways gender and sex have been investigated and represented by scientists and medical professionals. Going beyond the binary in historical explorations of sex and gender Beans Velocci of the School of Arts & Sciences explores how sex and gender have been shaped and categorized through history—and the consequences of those constructions taking on the guise of scientific and medical fact. Preterm birth drug Makena ignites argument over health equity Penn In the News Bloomberg Preterm birth drug Makena ignites argument over health equity Holly Fernandez Lynch of the Perelman School of Medicine says that there needs to be a truly expedited pathway for withdrawal once a drug is deemed unfit for the market. Five from Penn elected to National Academy of Medicine Regina Cunningham, Elizabeth Howell, Steven Joffe, Katalin Karikó, and Drew Weissman are the newest members of the National Academy of Medicine from Penn. Five from Penn elected to National Academy of Medicine Five Penn experts have been elected to the National Academy of Medicine for their contributions to the advancement of the medical sciences, health care, and public health. How can the latest Alzheimer’s therapy reach patients? Follow this trustworthy process Penn In the News STAT News How can the latest Alzheimer’s therapy reach patients? Follow this trustworthy process In an op-ed, Jason Karlawish of the Perelman School of Medicine outlines the reliable process required to properly evaluate the effects of lecanemab, a new Alzheimer’s drug already approved by the FDA. Biogen’s next Alzheimer drug feeds push for FDA approval revamp Penn In the News Bloomberg Biogen’s next Alzheimer drug feeds push for FDA approval revamp Emily Largent and Holly Fernandez Lynch of the Perelman School of Medicine are quoted about the clinical uncertainty of new Alzheimer’s drug findings and the FDA’s need to have post-approval trials underway. FDA seems poised to approve a new drug for ALS, but does it work? Penn In the News NPR FDA seems poised to approve a new drug for ALS, but does it work? Holly Fernandez Lynch of the Perelman School of Medicine says that the FDA’s current trajectory has been characterized by increased willingness to accept weaker evidence. Load More
Med schools should de-emphasize standardized admissions tests Penn In the News The Washington Post Med schools should de-emphasize standardized admissions tests In a cowritten Op-Ed, College of Arts and Sciences student Cameron Sabet urges medical schools to make their standardized tests pass/fail in order to remove barriers for disadvantaged minority applicants. A dynamic thinker Penn In the News Diverse: Issues in Higher Education A dynamic thinker A profile examines the career of Anita L. Allen of Penn Carey Law and the School of Arts & Sciences, who was recently named as one of two recipients of the Hastings Center’s 2022 Bioethics’ Founders Award. Tackling the ethical considerations of dementia research Tackling the ethical considerations of dementia research Alzheimer’s research poses tricky questions. Bedside-nurse-turned-bioethicist Emily Largent wants to answer them, and to improve the lives of Alzheimer’s patients. Going beyond the binary in historical explorations of sex and gender Beans Velocci, a faculty member in the Department of History and Sociology of Science, studies the complex and conflicting ways gender and sex have been investigated and represented by scientists and medical professionals. Going beyond the binary in historical explorations of sex and gender Beans Velocci of the School of Arts & Sciences explores how sex and gender have been shaped and categorized through history—and the consequences of those constructions taking on the guise of scientific and medical fact. Preterm birth drug Makena ignites argument over health equity Penn In the News Bloomberg Preterm birth drug Makena ignites argument over health equity Holly Fernandez Lynch of the Perelman School of Medicine says that there needs to be a truly expedited pathway for withdrawal once a drug is deemed unfit for the market. Five from Penn elected to National Academy of Medicine Regina Cunningham, Elizabeth Howell, Steven Joffe, Katalin Karikó, and Drew Weissman are the newest members of the National Academy of Medicine from Penn. Five from Penn elected to National Academy of Medicine Five Penn experts have been elected to the National Academy of Medicine for their contributions to the advancement of the medical sciences, health care, and public health. How can the latest Alzheimer’s therapy reach patients? Follow this trustworthy process Penn In the News STAT News How can the latest Alzheimer’s therapy reach patients? Follow this trustworthy process In an op-ed, Jason Karlawish of the Perelman School of Medicine outlines the reliable process required to properly evaluate the effects of lecanemab, a new Alzheimer’s drug already approved by the FDA. Biogen’s next Alzheimer drug feeds push for FDA approval revamp Penn In the News Bloomberg Biogen’s next Alzheimer drug feeds push for FDA approval revamp Emily Largent and Holly Fernandez Lynch of the Perelman School of Medicine are quoted about the clinical uncertainty of new Alzheimer’s drug findings and the FDA’s need to have post-approval trials underway. FDA seems poised to approve a new drug for ALS, but does it work? Penn In the News NPR FDA seems poised to approve a new drug for ALS, but does it work? Holly Fernandez Lynch of the Perelman School of Medicine says that the FDA’s current trajectory has been characterized by increased willingness to accept weaker evidence. Load More
A dynamic thinker Penn In the News Diverse: Issues in Higher Education A dynamic thinker A profile examines the career of Anita L. Allen of Penn Carey Law and the School of Arts & Sciences, who was recently named as one of two recipients of the Hastings Center’s 2022 Bioethics’ Founders Award. Tackling the ethical considerations of dementia research Tackling the ethical considerations of dementia research Alzheimer’s research poses tricky questions. Bedside-nurse-turned-bioethicist Emily Largent wants to answer them, and to improve the lives of Alzheimer’s patients. Going beyond the binary in historical explorations of sex and gender Beans Velocci, a faculty member in the Department of History and Sociology of Science, studies the complex and conflicting ways gender and sex have been investigated and represented by scientists and medical professionals. Going beyond the binary in historical explorations of sex and gender Beans Velocci of the School of Arts & Sciences explores how sex and gender have been shaped and categorized through history—and the consequences of those constructions taking on the guise of scientific and medical fact. Preterm birth drug Makena ignites argument over health equity Penn In the News Bloomberg Preterm birth drug Makena ignites argument over health equity Holly Fernandez Lynch of the Perelman School of Medicine says that there needs to be a truly expedited pathway for withdrawal once a drug is deemed unfit for the market. Five from Penn elected to National Academy of Medicine Regina Cunningham, Elizabeth Howell, Steven Joffe, Katalin Karikó, and Drew Weissman are the newest members of the National Academy of Medicine from Penn. Five from Penn elected to National Academy of Medicine Five Penn experts have been elected to the National Academy of Medicine for their contributions to the advancement of the medical sciences, health care, and public health. How can the latest Alzheimer’s therapy reach patients? Follow this trustworthy process Penn In the News STAT News How can the latest Alzheimer’s therapy reach patients? Follow this trustworthy process In an op-ed, Jason Karlawish of the Perelman School of Medicine outlines the reliable process required to properly evaluate the effects of lecanemab, a new Alzheimer’s drug already approved by the FDA. Biogen’s next Alzheimer drug feeds push for FDA approval revamp Penn In the News Bloomberg Biogen’s next Alzheimer drug feeds push for FDA approval revamp Emily Largent and Holly Fernandez Lynch of the Perelman School of Medicine are quoted about the clinical uncertainty of new Alzheimer’s drug findings and the FDA’s need to have post-approval trials underway. FDA seems poised to approve a new drug for ALS, but does it work? Penn In the News NPR FDA seems poised to approve a new drug for ALS, but does it work? Holly Fernandez Lynch of the Perelman School of Medicine says that the FDA’s current trajectory has been characterized by increased willingness to accept weaker evidence. Load More
Tackling the ethical considerations of dementia research Tackling the ethical considerations of dementia research Alzheimer’s research poses tricky questions. Bedside-nurse-turned-bioethicist Emily Largent wants to answer them, and to improve the lives of Alzheimer’s patients.
Going beyond the binary in historical explorations of sex and gender Beans Velocci, a faculty member in the Department of History and Sociology of Science, studies the complex and conflicting ways gender and sex have been investigated and represented by scientists and medical professionals. Going beyond the binary in historical explorations of sex and gender Beans Velocci of the School of Arts & Sciences explores how sex and gender have been shaped and categorized through history—and the consequences of those constructions taking on the guise of scientific and medical fact.
Preterm birth drug Makena ignites argument over health equity Penn In the News Bloomberg Preterm birth drug Makena ignites argument over health equity Holly Fernandez Lynch of the Perelman School of Medicine says that there needs to be a truly expedited pathway for withdrawal once a drug is deemed unfit for the market. Five from Penn elected to National Academy of Medicine Regina Cunningham, Elizabeth Howell, Steven Joffe, Katalin Karikó, and Drew Weissman are the newest members of the National Academy of Medicine from Penn. Five from Penn elected to National Academy of Medicine Five Penn experts have been elected to the National Academy of Medicine for their contributions to the advancement of the medical sciences, health care, and public health. How can the latest Alzheimer’s therapy reach patients? Follow this trustworthy process Penn In the News STAT News How can the latest Alzheimer’s therapy reach patients? Follow this trustworthy process In an op-ed, Jason Karlawish of the Perelman School of Medicine outlines the reliable process required to properly evaluate the effects of lecanemab, a new Alzheimer’s drug already approved by the FDA. Biogen’s next Alzheimer drug feeds push for FDA approval revamp Penn In the News Bloomberg Biogen’s next Alzheimer drug feeds push for FDA approval revamp Emily Largent and Holly Fernandez Lynch of the Perelman School of Medicine are quoted about the clinical uncertainty of new Alzheimer’s drug findings and the FDA’s need to have post-approval trials underway. FDA seems poised to approve a new drug for ALS, but does it work? Penn In the News NPR FDA seems poised to approve a new drug for ALS, but does it work? Holly Fernandez Lynch of the Perelman School of Medicine says that the FDA’s current trajectory has been characterized by increased willingness to accept weaker evidence. Load More
Five from Penn elected to National Academy of Medicine Regina Cunningham, Elizabeth Howell, Steven Joffe, Katalin Karikó, and Drew Weissman are the newest members of the National Academy of Medicine from Penn. Five from Penn elected to National Academy of Medicine Five Penn experts have been elected to the National Academy of Medicine for their contributions to the advancement of the medical sciences, health care, and public health.
How can the latest Alzheimer’s therapy reach patients? Follow this trustworthy process Penn In the News STAT News How can the latest Alzheimer’s therapy reach patients? Follow this trustworthy process In an op-ed, Jason Karlawish of the Perelman School of Medicine outlines the reliable process required to properly evaluate the effects of lecanemab, a new Alzheimer’s drug already approved by the FDA. Biogen’s next Alzheimer drug feeds push for FDA approval revamp Penn In the News Bloomberg Biogen’s next Alzheimer drug feeds push for FDA approval revamp Emily Largent and Holly Fernandez Lynch of the Perelman School of Medicine are quoted about the clinical uncertainty of new Alzheimer’s drug findings and the FDA’s need to have post-approval trials underway. FDA seems poised to approve a new drug for ALS, but does it work? Penn In the News NPR FDA seems poised to approve a new drug for ALS, but does it work? Holly Fernandez Lynch of the Perelman School of Medicine says that the FDA’s current trajectory has been characterized by increased willingness to accept weaker evidence. Load More
Biogen’s next Alzheimer drug feeds push for FDA approval revamp Penn In the News Bloomberg Biogen’s next Alzheimer drug feeds push for FDA approval revamp Emily Largent and Holly Fernandez Lynch of the Perelman School of Medicine are quoted about the clinical uncertainty of new Alzheimer’s drug findings and the FDA’s need to have post-approval trials underway. FDA seems poised to approve a new drug for ALS, but does it work? Penn In the News NPR FDA seems poised to approve a new drug for ALS, but does it work? Holly Fernandez Lynch of the Perelman School of Medicine says that the FDA’s current trajectory has been characterized by increased willingness to accept weaker evidence. Load More
FDA seems poised to approve a new drug for ALS, but does it work? Penn In the News NPR FDA seems poised to approve a new drug for ALS, but does it work? Holly Fernandez Lynch of the Perelman School of Medicine says that the FDA’s current trajectory has been characterized by increased willingness to accept weaker evidence.